BridgeBio Oncology Therapeutics Inc. (BBOT) vs Benitec Biopharma Inc. (BNTC)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Benitec Biopharma Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.60HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
BNTC
Benitec Biopharma Inc.
$9.23HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BBOT vs BNTC
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)BNTC +223.9% (+48.0%/yr)BNTC compounded faster over this window
Log scale — wide-divergence pair
BBOT BNTC
BBOT vs BNTC: by the numbers
- •BNTC is the larger company ($317M vs $288M market cap).
Metrics side by side
Valuation
| Metric | BBOT | BNTC |
|---|---|---|
| P/B ratio | 0.89 | 1.79 |
Profitability
| Metric | BBOT | BNTC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -25.73% |
| ROIC | -61.10% | -28.88% |
Growth (annualized)
| Metric | BBOT | BNTC |
|---|---|---|
| Total return CAGR (5Y) | N/A | -31.08% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.